JP2015517459A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015517459A5 JP2015517459A5 JP2015509461A JP2015509461A JP2015517459A5 JP 2015517459 A5 JP2015517459 A5 JP 2015517459A5 JP 2015509461 A JP2015509461 A JP 2015509461A JP 2015509461 A JP2015509461 A JP 2015509461A JP 2015517459 A5 JP2015517459 A5 JP 2015517459A5
- Authority
- JP
- Japan
- Prior art keywords
- ser
- aib
- pro
- glu
- ala
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims 20
- 239000012453 solvate Substances 0.000 claims 18
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 claims 7
- 208000008589 Obesity Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 235000020824 obesity Nutrition 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 5
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 5
- 150000001413 amino acids Chemical group 0.000 claims 4
- 206010012601 diabetes mellitus Diseases 0.000 claims 4
- 208000030159 metabolic disease Diseases 0.000 claims 4
- 239000008280 blood Substances 0.000 claims 3
- 210000004369 blood Anatomy 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 claims 2
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 claims 2
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims 2
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 108010094028 Prothrombin Proteins 0.000 claims 2
- 102100027378 Prothrombin Human genes 0.000 claims 2
- 239000000556 agonist Substances 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 208000016097 disease of metabolism Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 108010036598 gastric inhibitory polypeptide receptor Proteins 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 230000000770 proinflammatory effect Effects 0.000 claims 2
- 229940039716 prothrombin Drugs 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- -1 15- carboxy - pentadecanoyl Chemical group 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 108010074051 C-Reactive Protein Proteins 0.000 claims 1
- 102100032752 C-reactive protein Human genes 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 108010049003 Fibrinogen Proteins 0.000 claims 1
- 102000008946 Fibrinogen Human genes 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 208000002705 Glucose Intolerance Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 238000008214 LDL Cholesterol Methods 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims 1
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 claims 1
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 claims 1
- 208000001280 Prediabetic State Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 230000036772 blood pressure Effects 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 229940012952 fibrinogen Drugs 0.000 claims 1
- 208000020694 gallbladder disease Diseases 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 208000004104 gestational diabetes Diseases 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 201000009104 prediabetes syndrome Diseases 0.000 claims 1
- 201000002859 sleep apnea Diseases 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 150000003626 triacylglycerols Chemical class 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261642439P | 2012-05-03 | 2012-05-03 | |
| US61/642,439 | 2012-05-03 | ||
| US201361765561P | 2013-02-15 | 2013-02-15 | |
| US61/765,561 | 2013-02-15 | ||
| PCT/EP2013/059319 WO2013164483A1 (en) | 2012-05-03 | 2013-05-03 | Gip-glp-1 dual agonist compounds and methods |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015517459A JP2015517459A (ja) | 2015-06-22 |
| JP2015517459A5 true JP2015517459A5 (https=) | 2016-06-23 |
| JP6228187B2 JP6228187B2 (ja) | 2017-11-08 |
Family
ID=48325702
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015509461A Active JP6228187B2 (ja) | 2012-05-03 | 2013-05-03 | Ｇｉｐ−ｇｌｐ−１デュアルアゴニスト化合物及び方法 |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US10100097B2 (https=) |
| EP (1) | EP2844669B1 (https=) |
| JP (1) | JP6228187B2 (https=) |
| KR (1) | KR102184241B1 (https=) |
| CN (1) | CN104470948B (https=) |
| AR (1) | AR090937A1 (https=) |
| AU (1) | AU2013255751B2 (https=) |
| BR (1) | BR112014027348B1 (https=) |
| CA (1) | CA2872314C (https=) |
| EA (1) | EA028665B1 (https=) |
| HK (1) | HK1208232A1 (https=) |
| IL (1) | IL235463A0 (https=) |
| IN (1) | IN2014MN02304A (https=) |
| MX (1) | MX356641B (https=) |
| NZ (1) | NZ702333A (https=) |
| PH (1) | PH12014502452A1 (https=) |
| SG (1) | SG11201407137PA (https=) |
| TR (1) | TR201815338T4 (https=) |
| TW (1) | TWI689515B (https=) |
| WO (1) | WO2013164483A1 (https=) |
Families Citing this family (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010272944B2 (en) | 2009-07-13 | 2015-11-19 | Zealand Pharma A/S | Acylated glucagon analogues |
| IN2014MN02304A (https=) | 2012-05-03 | 2015-08-07 | Zealand Pharma As | |
| IN2015DN00544A (https=) | 2012-07-23 | 2015-06-26 | Zealand Pharma As | |
| TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| JP2016503046A (ja) * | 2012-12-19 | 2016-02-01 | ノヴォ ノルディスク アー／エス | コレステロール流出活性を有する新規ｇｌｐ−１受容体アゴニスト |
| AU2013366692B2 (en) * | 2012-12-21 | 2017-11-23 | Sanofi | Dual GLP1/GIP or trigonal GLP1/GIP/Glucagon agonists |
| SI3004155T1 (sl) | 2013-05-28 | 2022-02-28 | Takeda Pharmaceutical Company Limited | Peptidna spojina |
| PL3057984T3 (pl) | 2013-10-17 | 2018-12-31 | Zealand Pharma A/S | Acylowane analogi glukagonu |
| US9988429B2 (en) | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
| WO2015067715A2 (en) * | 2013-11-06 | 2015-05-14 | Zealand Pharma A/S | Gip-glp-1 dual agonist compounds and methods |
| CN105829339B (zh) * | 2013-11-06 | 2021-03-12 | 西兰制药公司 | 胰高血糖素-glp-1-gip三重激动剂化合物 |
| US10626156B2 (en) | 2013-12-06 | 2020-04-21 | Jie Han | Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs |
| KR102620911B1 (ko) * | 2014-10-29 | 2024-01-05 | 질랜드 파마 에이/에스 | Gip 효능제 화합물 및 방법 |
| TWI582109B (zh) * | 2015-01-09 | 2017-05-11 | 美國禮來大藥廠 | Ｇｉｐ及ｇｌｐ－１共促效劑化合物 |
| DK3283507T3 (da) | 2015-04-16 | 2020-01-02 | Zealand Pharma As | Acyleret glucagonanalog |
| JP2018529749A (ja) | 2015-10-07 | 2018-10-11 | シプルメット・ゲーエムベーハー | ペプチド薬物を経口送達するための医薬製剤 |
| TWI622596B (zh) | 2015-10-26 | 2018-05-01 | 美國禮來大藥廠 | 升糖素受體促效劑 |
| JP6995042B2 (ja) * | 2016-05-24 | 2022-02-04 | 武田薬品工業株式会社 | ペプチド化合物 |
| WO2018065634A1 (en) | 2016-10-07 | 2018-04-12 | Cyprumed Gmbh | Pharmaceutical compositions for the nasal delivery of peptide or protein drugs |
| GB201620611D0 (en) | 2016-12-05 | 2017-01-18 | Univ Of Lancaster | Treatment of neurological diseases |
| US11285180B2 (en) | 2016-12-06 | 2022-03-29 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods of enhancing the potency of incretin-based drugs in subjects in need thereof |
| JOP20190211A1 (ar) | 2017-03-31 | 2019-09-15 | Takeda Pharmaceuticals Co | ببتيد منشط لمستقبل gip |
| WO2019140030A1 (en) | 2018-01-12 | 2019-07-18 | Eli Lilly And Company | Combination therapy |
| US10577905B2 (en) | 2018-02-12 | 2020-03-03 | Eagle Technology, Llc | Hydrocarbon resource recovery system and RF antenna assembly with latching inner conductor and related methods |
| WO2019193204A1 (en) | 2018-04-06 | 2019-10-10 | Cyprumed Gmbh | Pharmaceutical compositions for the transmucosal delivery of therapeutic peptides and proteins |
| US11633459B2 (en) * | 2018-05-04 | 2023-04-25 | Novo Nordisk A/S | GIP derivatives and uses thereof |
| TWI705820B (zh) | 2018-06-22 | 2020-10-01 | 美商美國禮來大藥廠 | Gip/glp1促效劑組合物 |
| KR20240051304A (ko) * | 2018-07-23 | 2024-04-19 | 일라이 릴리 앤드 캄파니 | Gip/glp1 공효능제 화합물 |
| CN119499352A (zh) | 2018-07-23 | 2025-02-25 | 伊莱利利公司 | 使用gip/glp1共激动剂用于糖尿病的方法 |
| SG11202100112YA (en) | 2018-07-23 | 2021-02-25 | Lilly Co Eli | Methods of using a gip/glp1 co-agonist for therapy |
| US12122815B2 (en) | 2018-09-24 | 2024-10-22 | Takeda Pharmaceutical Company Limited | GIP receptor agonist peptide compounds and uses thereof |
| AU2020206388B2 (en) | 2019-01-07 | 2022-12-01 | Vitalixir (Beijing) Co., Ltd | Novel polypeptide and therapeutic uses thereof |
| CN112351994B (zh) * | 2019-04-11 | 2024-06-07 | 江苏豪森药业集团有限公司 | 一种多受体激动剂及其医药用途 |
| AR119471A1 (es) | 2019-08-01 | 2021-12-22 | Lilly Co Eli | Compuestos agonistas de gipr |
| KR102812908B1 (ko) | 2019-08-19 | 2025-05-28 | 일라이 릴리 앤드 캄파니 | 인크레틴 유사체의 제조 방법 |
| KR20210040818A (ko) | 2019-10-04 | 2021-04-14 | 한미약품 주식회사 | 글루카곤, 및 glp-1 수용체 및 gip 수용체 이중 작용제를 포함하는 조성물 및 이의 치료학적 용도 |
| CN110684082B (zh) | 2019-10-08 | 2021-12-10 | 江苏诺泰澳赛诺生物制药股份有限公司 | Gip和glp-1双激动多肽化合物及药学上可接受的盐与用途 |
| CR20220206A (es) | 2019-11-11 | 2022-06-16 | Boehringer Ingelheim Int | Agonistas del receptor npy2 |
| CN113383014B (zh) * | 2019-11-15 | 2024-06-18 | 江苏豪森药业集团有限公司 | 双受体重激动剂化合物及其药物组合物 |
| US20250346647A2 (en) * | 2019-12-03 | 2025-11-13 | Antag Therapeutics Aps | Optimized GIP Peptide Analogues |
| WO2021143810A1 (zh) * | 2020-01-17 | 2021-07-22 | 珠海联邦制药股份有限公司 | 多肽化合物及其应用 |
| IL294955A (en) * | 2020-01-23 | 2022-09-01 | Lilly Co Eli | Cobalt-agonist gip/glp1 compounds |
| TW202140058A (zh) | 2020-01-30 | 2021-11-01 | 美商美國禮來大藥廠 | 提派肽（ｔｉｒｚｅｐａｔｉｄｅ）之治療用途 |
| CN115335395A (zh) * | 2020-03-25 | 2022-11-11 | 武田药品工业株式会社 | Gip受体激动剂肽化合物的qd给药及其用途 |
| TW202216746A (zh) * | 2020-06-22 | 2022-05-01 | 印度商太陽製藥工業有限公司 | 長效型ｇｌｐ－１／ｇｉｐ雙重促效劑 |
| US20230346961A1 (en) | 2020-07-22 | 2023-11-02 | Novo Nordisk A/S | Glp-1 and gip receptor co-agonists |
| EP4185607A1 (en) | 2020-07-22 | 2023-05-31 | Novo Nordisk A/S | Co-agonists at glp-1 and gip receptors suitable for oral delivery |
| JP7661478B2 (ja) | 2020-08-07 | 2025-04-14 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 可溶性ｎｐｙ２受容体アゴニスト |
| EP4210680A1 (en) | 2020-09-07 | 2023-07-19 | Cyprumed GmbH | Improved pharmaceutical formulations of glp-1 receptor agonists |
| PE20231309A1 (es) | 2020-10-17 | 2023-08-24 | Sun Pharmaceutical Ind Ltd | Agonistas duales glp-1/gip |
| MX2023006419A (es) * | 2020-12-02 | 2023-08-15 | Dongbao Purple Star Hangzhou Biopharmaceutical Co Ltd | Compuestos polipéptidos modificados con lactama. |
| CN114617956B (zh) * | 2020-12-10 | 2023-10-03 | 江苏中新医药有限公司 | 一种高效降糖的蛋白质药物 |
| JP7573760B2 (ja) * | 2020-12-23 | 2024-10-25 | 浙江道尓生物科技有限公司 | 長時間作用型グルカゴン誘導体 |
| CA3204051A1 (en) | 2021-01-20 | 2022-07-28 | Brian Lian | Compositions and methods for the treatment of metabolic and liver disorders |
| AU2022269659B2 (en) | 2021-05-07 | 2025-04-10 | Eli Lilly And Company | Erodible tablet |
| IL306122B2 (en) * | 2021-05-28 | 2026-01-01 | Guangdong Raynovent Biotech Co Ltd | Preparation and use of polypeptide |
| EP4345105A4 (en) * | 2021-06-01 | 2025-04-23 | Nanjing Zhihe Medicine Technology Co., Ltd | Polypeptide derivative with dual targeted activation of GLP-1R and GIPR, manufacturing process therefor and use thereof |
| US20250223331A1 (en) * | 2021-09-02 | 2025-07-10 | Sunshine Lake Pharma Co., Ltd. | Glp-1/gip dual-targeted polypeptide and fusion protein and applications thereof |
| JP7642830B2 (ja) | 2021-09-15 | 2025-03-10 | バイキング・セラピューティクス・インコーポレイテッド | 代謝及び肝臓障害の処置のための組成物及び方法 |
| US20250115654A1 (en) * | 2021-11-12 | 2025-04-10 | Fujian Shengdi Pharmaceutical Co., Ltd. | Pharmaceutical composition of glp-1 receptor and gip receptor dual agonist, and use thereof |
| TW202330584A (zh) | 2022-01-20 | 2023-08-01 | 丹麥商諾佛 儂迪克股份有限公司 | 前藥及其用途 |
| CN116947978A (zh) * | 2022-04-19 | 2023-10-27 | 北京惠之衡生物科技有限公司 | 一种glp-1和gip受体共激动多肽衍生物及其盐和制剂 |
| EP4556487A1 (en) | 2022-07-13 | 2025-05-21 | Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. | Glp-1/gip dual agonist, and preparation method therefor and use thereof |
| KR20250047843A (ko) * | 2022-07-15 | 2025-04-04 | 펩2탱고 테라퓨틱스 인크. | 다중-효능제 펩티드를 포함하는 조성물 및 제조 및 사용 방법 |
| WO2024020388A1 (en) * | 2022-07-20 | 2024-01-25 | Viking Therapeutics, Inc. | Pharmaceutical formulations and methods for the treatment of metabolic and liver disorders |
| JP2025530743A (ja) | 2022-08-29 | 2025-09-17 | イーライ リリー アンド カンパニー | 経口投与のための組成物 |
| CN119894921A (zh) | 2022-09-15 | 2025-04-25 | 伊莱利利公司 | Gip和glp-1双重激动剂化合物 |
| CN118255864A (zh) * | 2022-12-26 | 2024-06-28 | 杭州中美华东制药有限公司 | Gip受体激动剂及其用途 |
| JP2026502943A (ja) | 2022-12-30 | 2026-01-27 | アルギファルマ エーエス | 経口投与されるポリペプチド治療剤の全身バイオアベイラビリティを高める組成物および方法 |
| US20240270821A1 (en) | 2023-01-31 | 2024-08-15 | Eli Lilly And Company | Gip/glp1/gcg tri-receptor agonists and uses thereof |
| WO2024165571A2 (en) | 2023-02-06 | 2024-08-15 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| EP4687947A1 (en) | 2023-04-05 | 2026-02-11 | Antag Therapeutics ApS | Gip activity modulators and orthostatic intolerance |
| EP4714434A1 (en) | 2023-05-19 | 2026-03-25 | Aulbio Co., Ltd. | Microsphere comprising thyrazepatide, method for preparing same, and pharmaceutical composition comprising same |
| KR20260022948A (ko) | 2023-06-09 | 2026-02-20 | 썬 파마슈티컬 인더스트리스 리미티드 | Glp-1/gip 이중 수용체 작용제, glp-1/gcg 이중 수용체 작용제, 및 glp-1/gip/gcg 삼중 수용체 작용제 |
| TW202517291A (zh) | 2023-06-30 | 2025-05-01 | 丹麥商西蘭製藥公司 | 組合療法 |
| CN116693652B (zh) * | 2023-08-02 | 2024-01-05 | 北京惠之衡生物科技有限公司 | 一种glp-1/gip受体双重激动剂衍生物及其制备方法和应用 |
| CN117646017A (zh) * | 2023-11-02 | 2024-03-05 | 中国人民解放军海军军医大学 | Gip/glp-1双激动剂多肽编码基因、及其重组乳酸菌和应用 |
| TW202540155A (zh) | 2023-11-30 | 2025-10-16 | 丹麥商諾佛 儂迪克股份有限公司 | Glp-1、gip及澱粉素受體之三重促效劑 |
| WO2025125576A2 (en) | 2023-12-15 | 2025-06-19 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| EP4686757A1 (en) | 2024-07-31 | 2026-02-04 | e-therapeutics PLC | Inhibitors of expression and/or function |
| WO2025133348A1 (en) | 2023-12-22 | 2025-06-26 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| WO2025196502A1 (en) | 2024-03-20 | 2025-09-25 | North Carolina Agricultural & Technical State University | Choline kinase inhibitors as a therapeutic treatment for obesity |
Family Cites Families (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ202757A (en) | 1981-12-23 | 1985-11-08 | Novo Industri As | Peptides and medicaments |
| IL128332A0 (en) | 1996-08-30 | 2000-01-31 | Novo Nordisk As | GLP-1 derivatives |
| AU723268B2 (en) | 1996-09-09 | 2000-08-24 | Zealand Pharma A/S | Improved solid-phase peptide synthesis and agent for use in such synthesis |
| EP0932614A1 (en) | 1996-09-09 | 1999-08-04 | Zealand Pharmaceuticals A/S | Peptide prodrugs containing an alpha-hydroxyacid linker |
| MXPA00004670A (es) | 1997-11-14 | 2003-07-14 | Amylin Pharmaceuticals Inc | Compuestos agonistas de exendina novedosos. |
| NZ506839A (en) | 1998-03-09 | 2003-05-30 | Zealand Pharma As | Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
| CZ295044B6 (cs) | 1998-12-07 | 2005-05-18 | Societe De Conseils De Recherches Et D'application | Analogy GLP-1, mající kyselinu aminoizomáselnou na pozicích 8 a 35, jejich použití a farmaceutické prostředky je obsahující |
| US6451987B1 (en) | 1999-03-15 | 2002-09-17 | Novo Nordisk A/S | Ion exchange chromatography of proteins and peptides |
| CZ20013018A3 (cs) | 1999-03-17 | 2002-02-13 | Novo Nordisk A/S | Způsob pro acylování aminoskupiny peptidu nebo proteinu a sloučenina |
| EP1076066A1 (en) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
| GB0121709D0 (en) | 2001-09-07 | 2001-10-31 | Imp College Innovations Ltd | Food inhibition agent |
| AU2002346491A1 (en) | 2001-12-19 | 2003-07-09 | Eli Lilly And Company | Crystalline compositions for controlling blood glucose |
| CZ2004710A3 (cs) | 2001-12-20 | 2005-02-16 | Eli Lilly And Company | Inzulínová sloučenina s protrahovaným účinkem |
| GB0300571D0 (en) | 2003-01-10 | 2003-02-12 | Imp College Innovations Ltd | Modification of feeding behaviour |
| EP1620465A2 (en) | 2003-04-29 | 2006-02-01 | Eli Lilly And Company | Insulin analogs having protracted time action |
| MX2007005521A (es) | 2004-11-12 | 2007-05-18 | Novo Nordisk As | Formulaciones estables de peptidos insulinotropicos. |
| CN101155828A (zh) * | 2005-02-11 | 2008-04-02 | 安米林药品公司 | Gip类似物和具有可选择性质的杂合多肽 |
| TWI362392B (en) | 2005-03-18 | 2012-04-21 | Novo Nordisk As | Acylated glp-1 compounds |
| CA2607566A1 (en) * | 2005-05-06 | 2006-11-16 | Bayer Pharmaceuticals Corporation | Glucagon-like peptide 1 (glp-1) receptor agonists and their pharmacological methods of use |
| ATE553124T1 (de) | 2005-06-13 | 2012-04-15 | Imp Innovations Ltd | Oxyntomodulinanaloga und ihre wirkungen auf das fressverhalten |
| US20090202497A1 (en) | 2005-08-23 | 2009-08-13 | The General Hospital Corporation | Use of glp-1, glp-1 derivatives or glp-1 fragments for skin regeneration, stimulation of hair growth, or treatment of diabetes |
| CA2913805A1 (en) | 2005-11-07 | 2007-05-18 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting physiological solubility and stability |
| WO2007081824A2 (en) | 2006-01-06 | 2007-07-19 | Case Western Reserve University | Fibrillation resistant proteins |
| CA2638800A1 (en) | 2006-02-22 | 2007-09-07 | Merck & Co., Inc. | Oxyntomodulin derivatives |
| WO2007109354A2 (en) * | 2006-03-21 | 2007-09-27 | Amylin Pharmaceuticals, Inc. | Peptide-peptidase inhibitor conjugates and methods of using same |
| MX2009000709A (es) | 2006-07-18 | 2009-02-04 | Sanofi Aventis | Anticuerpo antagonista contra epha2 para el tratamiento de cancer. |
| ITMI20061607A1 (it) | 2006-08-09 | 2008-02-10 | Maria Vincenza Carriero | Peptidi con attivita farmacologica |
| WO2008023050A1 (en) * | 2006-08-25 | 2008-02-28 | Novo Nordisk A/S | Acylated exendin-4 compounds |
| WO2008043033A2 (en) | 2006-10-04 | 2008-04-10 | Case Western Reserve University | Fibrillation-resistant insulin and insulin analogues |
| TWI428346B (zh) | 2006-12-13 | 2014-03-01 | Imp Innovations Ltd | 新穎化合物及其等對進食行為影響 |
| CA2677932A1 (en) | 2007-02-15 | 2008-08-21 | Indiana University Research And Technology Corporation | Glucagon/glp-1 receptor co-agonists |
| EP2025684A1 (en) | 2007-08-15 | 2009-02-18 | Zealand Pharma A/S | Glucagon analogues |
| EP2158214B1 (en) | 2007-06-15 | 2011-08-17 | Zealand Pharma A/S | Glucagon analogues |
| MX2010005317A (es) | 2007-11-20 | 2010-06-02 | Ambrx Inc | Polipeptidos de insulina modificados y sus usos. |
| DE102008003566A1 (de) | 2008-01-09 | 2009-07-16 | Sanofi-Aventis Deutschland Gmbh | Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil |
| JP5695909B2 (ja) | 2008-01-09 | 2015-04-08 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 極度に遅延した時間作用プロファイルを有する新規なインスリン誘導体 |
| DE102008003568A1 (de) | 2008-01-09 | 2009-07-16 | Sanofi-Aventis Deutschland Gmbh | Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil |
| MY152979A (en) | 2008-01-09 | 2014-12-15 | Sanofi Aventis Deutschland | Novel insulin derivatives having an extremely delayed time-action profile |
| US8993516B2 (en) | 2008-04-14 | 2015-03-31 | Case Western Reserve University | Meal-time insulin analogues of enhanced stability |
| EP2296692A4 (en) | 2008-04-22 | 2012-06-06 | Univ Case Western Reserve | ISOFORM-SPECIFIC INSULIN ANALOG |
| TWI451876B (zh) | 2008-06-13 | 2014-09-11 | Lilly Co Eli | 聚乙二醇化之離脯胰島素化合物 |
| CN102105159B (zh) * | 2008-06-17 | 2015-07-08 | 印第安纳大学研究及科技有限公司 | 基于gip的混合激动剂用于治疗代谢紊乱和肥胖症 |
| US8450270B2 (en) | 2008-06-17 | 2013-05-28 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility and stability in physiological pH buffers |
| AR072160A1 (es) | 2008-06-17 | 2010-08-11 | Univ Indiana Res & Tech Corp | Co-agonistas del receptor de glucagon/glp-1 |
| PL219335B1 (pl) | 2008-07-04 | 2015-04-30 | Inst Biotechnologii I Antybiotyków | Pochodna insuliny lub jej farmaceutycznie dopuszczalna sól, jej zastosowanie oraz zawierająca ją kompozycja farmaceutyczna |
| MX2011001181A (es) | 2008-07-31 | 2011-04-05 | Univ Case Western Reserve | Insulina estabilizada con halogeno. |
| WO2010016940A2 (en) * | 2008-08-07 | 2010-02-11 | Ipsen Pharma S.A.S. | Analogues of glucose-dependent insulinotropic polypeptide |
| ES2561208T3 (es) | 2008-09-12 | 2016-02-25 | Novo Nordisk A/S | Método de acilación de un péptido o una proteína |
| EP2370462B1 (en) | 2008-12-15 | 2014-07-16 | Zealand Pharma A/S | Glucagon analogues |
| CN102282167B (zh) | 2008-12-15 | 2014-08-13 | 西兰制药公司 | 胰高血糖素类似物 |
| JP5635531B2 (ja) | 2008-12-15 | 2014-12-03 | ジーランド ファーマ アクティーゼルスカブ | グルカゴン類似体 |
| ES2477880T3 (es) | 2008-12-15 | 2014-07-18 | Zealand Pharma A/S | Análogos del glucagón |
| JP5789515B2 (ja) | 2008-12-19 | 2015-10-07 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ | インスリン類似体 |
| AU2009335715B2 (en) | 2008-12-19 | 2016-09-15 | Indiana University Research And Technology Corporation | Amide-based insulin prodrugs |
| US20100240883A1 (en) | 2009-03-18 | 2010-09-23 | Nian Wu | Lipid-drug conjugates for drug delivery |
| CN101519446A (zh) | 2009-03-31 | 2009-09-02 | 上海一就生物医药有限公司 | 一种重组人胰岛素及其类似物的制备方法 |
| EP2443146B1 (en) | 2009-06-16 | 2016-10-05 | Indiana University Research And Technology Corporation | Gip receptor-active glucagon compounds |
| AU2010272944B2 (en) | 2009-07-13 | 2015-11-19 | Zealand Pharma A/S | Acylated glucagon analogues |
| JP6006118B2 (ja) | 2009-12-16 | 2016-10-12 | ノヴォ ノルディスク アー／エス | Ｇｌｐ−１アナログ及び誘導体 |
| US20130157953A1 (en) | 2010-01-20 | 2013-06-20 | Zealand Pharma A/S | Treatment of cardiac conditions |
| KR20120123443A (ko) * | 2010-01-27 | 2012-11-08 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 대사 장애 및 비만 치료용 글루카곤 길항제-ｇｉｐ 항진제 콘쥬게이트 |
| CN102933598A (zh) | 2010-03-26 | 2013-02-13 | 诺沃—诺迪斯克有限公司 | 新型胰高血糖素类似物 |
| AR080592A1 (es) | 2010-03-26 | 2012-04-18 | Lilly Co Eli | Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso |
| AU2011247824B2 (en) | 2010-04-27 | 2014-02-13 | Betta Pharmaceuticals Co., Ltd | Glucagon-like peptide-1 analogue and use thereof |
| UY33462A (es) | 2010-06-23 | 2012-01-31 | Zealand Pharma As | Analogos de glucagon |
| US9169310B2 (en) | 2010-06-24 | 2015-10-27 | Zealand Pharma A/S | Glucagon analogues |
| JP6039569B2 (ja) | 2010-11-09 | 2016-12-07 | ノヴォ ノルディスク アー／エス | 二重アシル化されたｇｌｐ−１誘導体 |
| KR20140043709A (ko) | 2011-01-20 | 2014-04-10 | 질랜드 파마 에이/에스 | 아실화 글루카곤 유사체와 인슐린 유사체의 조합 |
| RU2013145013A (ru) | 2011-03-28 | 2015-05-10 | Ново Нордиск А/С | Новые аналоги глюкагона |
| PL2696687T3 (pl) | 2011-04-12 | 2017-06-30 | Novo Nordisk A/S | Pochodne podwójnie acylowanej GLP-1 |
| WO2012150503A2 (en) | 2011-05-03 | 2012-11-08 | Zealand Pharma A/S | Glu-glp-1 dual agonist signaling-selective compounds |
| US9453062B2 (en) * | 2011-06-10 | 2016-09-27 | Beijing Hanmi Pharmaceutical Co., Ltd. | Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof |
| AU2012311484B2 (en) | 2011-09-23 | 2017-04-13 | Novo Nordisk A/S | Novel glucagon analogues |
| IN2014CN04401A (https=) | 2011-12-23 | 2015-09-04 | Zealand Pharma As | |
| IN2014MN02304A (https=) | 2012-05-03 | 2015-08-07 | Zealand Pharma As | |
| IN2015DN00544A (https=) | 2012-07-23 | 2015-06-26 | Zealand Pharma As | |
| TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
| PL3057984T3 (pl) | 2013-10-17 | 2018-12-31 | Zealand Pharma A/S | Acylowane analogi glukagonu |
| US9988429B2 (en) | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
| WO2015067715A2 (en) | 2013-11-06 | 2015-05-14 | Zealand Pharma A/S | Gip-glp-1 dual agonist compounds and methods |
| MX2016010599A (es) | 2014-02-18 | 2016-11-18 | Novo Nordisk As | Analogos de glucagon estables y uso para el tratamiento de hipoglucemia. |
| DK3283507T3 (da) | 2015-04-16 | 2020-01-02 | Zealand Pharma As | Acyleret glucagonanalog |
-
2013
- 2013-05-03 IN IN2304MUN2014 patent/IN2014MN02304A/en unknown
- 2013-05-03 MX MX2014013318A patent/MX356641B/es active IP Right Grant
- 2013-05-03 TW TW102115949A patent/TWI689515B/zh active
- 2013-05-03 KR KR1020147033952A patent/KR102184241B1/ko active Active
- 2013-05-03 AR ARP130101524A patent/AR090937A1/es unknown
- 2013-05-03 CN CN201380032714.4A patent/CN104470948B/zh active Active
- 2013-05-03 TR TR2018/15338T patent/TR201815338T4/tr unknown
- 2013-05-03 AU AU2013255751A patent/AU2013255751B2/en active Active
- 2013-05-03 EP EP13720931.8A patent/EP2844669B1/en active Active
- 2013-05-03 BR BR112014027348-0A patent/BR112014027348B1/pt active IP Right Grant
- 2013-05-03 JP JP2015509461A patent/JP6228187B2/ja active Active
- 2013-05-03 US US14/398,260 patent/US10100097B2/en active Active
- 2013-05-03 SG SG11201407137PA patent/SG11201407137PA/en unknown
- 2013-05-03 WO PCT/EP2013/059319 patent/WO2013164483A1/en not_active Ceased
- 2013-05-03 NZ NZ702333A patent/NZ702333A/en unknown
- 2013-05-03 EA EA201491918A patent/EA028665B1/ru not_active IP Right Cessation
- 2013-05-03 CA CA2872314A patent/CA2872314C/en active Active
- 2013-05-03 HK HK15108788.2A patent/HK1208232A1/xx unknown
-
2014
- 2014-11-02 IL IL235463A patent/IL235463A0/en unknown
- 2014-11-03 PH PH12014502452A patent/PH12014502452A1/en unknown
-
2018
- 2018-09-05 US US16/121,745 patent/US20190135886A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015517459A5 (https=) | ||
| JP2020045362A5 (https=) | ||
| JP2013517307A5 (https=) | ||
| JP2023126965A5 (https=) | ||
| TWI689515B (zh) | Ｇｉｐ-ｇｌｐ-１雙重促效劑化合物及方法 | |
| JP2021138740A5 (https=) | ||
| JP2020040979A (ja) | Ｇｉｐ−ｇｌｐ−１デュアルアゴニスト化合物及び方法 | |
| HRP20171499T1 (hr) | Protutijela za humani gdf8 | |
| WO2009043463A3 (en) | Use of gluten exorphin c : as a therapeutic agent | |
| JP2012520866A5 (https=) | ||
| WO2009033711A3 (en) | Use of glp-1 as a therapeutic agent | |
| WO2009043466A3 (en) | Therapeutic use of the peptide gluten exorphin a5 | |
| WO2009033762A3 (en) | Use of endothelin-3 as a therapeutic agent | |
| WO2009040048A3 (en) | Use of the c-reactive peptide as a therapeutic agent | |
| WO2009033739A3 (en) | Use of a peptide as a therapeutic agent | |
| WO2009049742A3 (en) | Use of melanotrophin-potentiating factor as a therapeutic agent | |
| WO2009033764A3 (en) | Use of a peptide as a therapeutic agent | |
| JP2013518090A5 (https=) | ||
| WO2009046832A3 (en) | Short peptides used in medicine | |
| JP2019533722A5 (https=) | ||
| JP2014506579A5 (https=) | ||
| JP2017500289A5 (https=) | ||
| JP6768646B2 (ja) | Ｐｇｉ２受容体に関連した状態の治療法 | |
| JP2016519106A5 (https=) | ||
| WO2009046858A3 (en) | Therapeutic uses of kisspeptin 13 and compositions thereof |